Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- A very old disease
- Outline
- Discovery of streptomycin and the first RCT
- The streptomycin trial: the 6 month results
- The streptomycin trial: the 5 year results
- Streptomycin and PAS
- The acquisition of streptomycin resistance
- Streptomycin, PAS and isoniazid
- Changes in mortality from TB in the UK
- From research to practice
- MRC chronic trial
- Results of the MRC chronic trial
- The advent of short course chemotherapy
- Short course chemotherapy: the first trial
- First East African short course trial
- How could these results best be compared?
- The non inferiority design
- Non-inferiority: first East African trial analysis
- First East African short course study
- The search for cheap but effective regimens
- Treatment from 1972 to 2010
- If 6 months works, why not 4?
- Fourth East African short course
- Trying again
- Slow to adopt
- Still waiting
- Two unanswered questions
- Treatment duration issues
- Intermittent chemotherapy (1)
- Intermittent chemotherapy (2)
- New cases of tuberculosis in Zambia
- Association between HIV and TB
- Treatment duration issues for HIV coinfection (1)
- Treatment duration issues for HIV coinfection (2)
- The need for programmed based trials
- Sahara study
- Treating refugees in a war zone
- The slow road to TB diagnosis
- Smear negative disease
- New regimens (the role of the mouse)
- How do we choose the regimens to phase III?
- MAMS (multi-arm multi-stage) trials
- Phase III TB trials
- The role of observational data
- "A gulf which has been much underestimated"
- East African and other drug resistance surveys
- Kenya RCT programme results
- Treating multidrug resistant TB
- The STREAM trial
- One drug - one shot in the dark?
Topics Covered
- Early trials demonstrated the need for giving more than one drug to avoid the problems of acquired drug resistance
- Short course chemotherapy highly effective provided rifampicin given throughout
- HIV coinfection has presented new challenges to effective treatment
- New methods needed to identify potential regimen candidates for phase III
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Nunn, A. (2013, February 28). The development of current treatments for tuberculosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/QGHY7370.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Andrew Nunn has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.